Brokerages Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $7.06

Vor Biopharma Inc. (NYSE:VOR) has received an average recommendation of “Hold” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $7.06.

A number of equities research analysts recently commented on the stock. Wedbush restated a “neutral” rating and set a $0.40 price objective (down from $7.00) on shares of Vor Biopharma in a report on Thursday, May 8th. Jones Trading downgraded shares of Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 8th. HC Wainwright reaffirmed a “neutral” rating on shares of Vor Biopharma in a research report on Friday, May 9th. JMP Securities reaffirmed a “market perform” rating and issued a $6.00 target price on shares of Vor Biopharma in a research report on Friday, May 9th. Finally, Stifel Nicolaus decreased their target price on shares of Vor Biopharma from $12.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 21st.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VOR. Virtu Financial LLC bought a new position in shares of Vor Biopharma in the 4th quarter valued at about $60,000. XTX Topco Ltd bought a new position in shares of Vor Biopharma in the 4th quarter valued at about $80,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of Vor Biopharma in the 4th quarter valued at about $33,000. Lynx1 Capital Management LP bought a new position in shares of Vor Biopharma in the 4th quarter valued at about $707,000. Finally, Northern Trust Corp grew its position in shares of Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after acquiring an additional 44,252 shares during the period. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Down 13.3%

Shares of NYSE:VOR opened at $0.18 on Tuesday. Vor Biopharma has a 12 month low of $0.13 and a 12 month high of $1.80. The company’s fifty day simple moving average is $0.40 and its 200 day simple moving average is $0.86. The firm has a market cap of $22.76 million, a price-to-earnings ratio of -0.11 and a beta of -0.51.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.